Net Cash Provided by (Used in) Financing Activities in USD of ARROWHEAD PHARMACEUTICALS, INC. from 2016 to 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
ARROWHEAD PHARMACEUTICALS, INC. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2016 to 2025.
  • ARROWHEAD PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Dec 2024 was $20.6M, a 7628% increase year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $74M, a 91.5% decline from 2024.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $871M, a 244% increase from 2023.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $253M, a 288% increase from 2022.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $20.6M +$20.4M +7628% 01 Oct 2024 31 Dec 2024 10-Q 10 Feb 2025
Q4 2023 $267K -$250M -99.9% 01 Oct 2023 31 Dec 2023 10-Q 10 Feb 2025
Q4 2022 $251M +$249M +13193% 01 Oct 2022 31 Dec 2022 10-Q 06 Feb 2024
Q4 2021 $1.89M -$3.22M -63.1% 01 Oct 2021 31 Dec 2021 10-Q 06 Feb 2023
Q4 2020 $5.1M -$248M -98% 01 Oct 2020 31 Dec 2020 10-Q 02 Feb 2022
Q4 2019 $253M +$194M +329% 01 Oct 2019 31 Dec 2019 10-Q 04 Feb 2021
Q4 2018 $59.1M +$59.1M 01 Oct 2018 31 Dec 2018 10-Q 05 Feb 2020
Q4 2017 $26.3K* 01 Oct 2017 31 Dec 2017 10-Q 07 Feb 2019

ARROWHEAD PHARMACEUTICALS, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 $74M -$797M -91.5% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025
2024 $871M +$617M +244% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025
2023 $253M +$188M +288% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025
2022 $65.2M +$53.9M +477% 01 Oct 2021 30 Sep 2022 10-K 26 Nov 2024
2021 $11.3M -$247M -95.6% 01 Oct 2020 30 Sep 2021 10-K 29 Nov 2023
2020 $258M +$192M +289% 01 Oct 2019 30 Sep 2020 10-K 28 Nov 2022
2019 $66.4M +$6.43M +10.7% 01 Oct 2018 30 Sep 2019 10-K 22 Nov 2021
2018 $60M +$47.9M +397% 01 Oct 2017 30 Sep 2018 10-K 23 Nov 2020
2017 $12.1M -$43.1M -78.1% 01 Oct 2016 30 Sep 2017 10-K 25 Nov 2019
2016 $55.1M 01 Oct 2015 30 Sep 2016 10-K 11 Dec 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.